Company Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.
The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Dr. David Apelian M.B.A., M.D., Ph.D. |
Contact Details
Address: 2155 Park Boulevard Palo Alto, California 94306 United States | |
| Phone | 650-279-9845 |
| Website | eigerbio.com |
Stock Details
| Ticker Symbol | EIGRQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001305253 |
| ISIN Number | US28249U2042 |
| Employer ID | 36-1004130 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Apelian M.B.A., M.D., Ph.D. | Chief Executive Officer and Director |
| William G. Kaichoff CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Christopher A. Kurtz | Chief Technical Officer |
| James Vollins J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | 8-K | Current Report |
| Jul 10, 2024 | 8-K | Current Report |
| Jul 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 28, 2024 | 8-K | Current Report |
| May 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 8, 2024 | 8-K | Current Report |
| May 2, 2024 | 8-K | Current Report |